Latest news and press releases about Cumberland Pharmaceuticals Inc. (CPIX): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Cumberland Pharmaceuticals Inc. functions as a specialized pharmaceutical enterprise, primarily involved in the procurement, advancement, and commercialization of prescription medications. Its strategic focus areas include acute hospital care, gastroenterology, rheumatology, and oncology, with operations spanning both the United States and global markets. The company's existing product line includes: Acetadote: an injectable solution for treating acetaminophen poisoning.
Price
| Price | $6.98 |
| Market Cap | $105M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 6.05 |
| EV / EBITDA | -17.72 |
| Dividend Yield | 21.30% |
Profitability
| Return on Equity | -47.10% |
| Return on Invested Capital | -34.15% |
| Return on Assets | -16.87% |
| Gross Margin | 83.37% |
| Operating Margin | -30.79% |
| Net Margin | -33.92% |
Related companies: ABVC · CALC · CELU · DYAI · LTRN · LVTX · NOTV
Explore sector: Healthcare · Drug Manufacturers - Specialty & Generic
More sections of CPIX: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks